GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Price-to-Free-Cash-Flow

Prostatype Genomics AB (OSTO:PROGEN) Price-to-Free-Cash-Flow : N/A (As of Jun. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Price-to-Free-Cash-Flow?

As of today (2024-06-11), Prostatype Genomics AB's share price is kr0.046. Prostatype Genomics AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was kr-0.32. Hence, Prostatype Genomics AB's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Prostatype Genomics AB's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 5 years, Prostatype Genomics AB's highest Price-to-Free-Cash-Flow Ratio was 63.94. The lowest was 25.21. And the median was 44.94.

OSTO:PROGEN's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 25.59
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Prostatype Genomics AB's Free Cash Flow per Share for the three months ended in Jun. 2023 was kr-0.06. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was kr-0.32.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -16.20% per year.

During the past 5 years, Prostatype Genomics AB's highest 3-Year average Free Cash Flow per Share Growth Rate was -16.20% per year. The lowest was -85.30% per year. And the median was -50.75% per year.


Prostatype Genomics AB Price-to-Free-Cash-Flow Historical Data

The historical data trend for Prostatype Genomics AB's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Price-to-Free-Cash-Flow Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Prostatype Genomics AB Quarterly Data
Jun18 Jun19 Mar20 Jun20 Sep20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Prostatype Genomics AB's Price-to-Free-Cash-Flow

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostatype Genomics AB's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Price-to-Free-Cash-Flow falls into.



Prostatype Genomics AB Price-to-Free-Cash-Flow Calculation

Prostatype Genomics AB's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.046/-0.316
=N/A

Prostatype Genomics AB's Share Price of today is kr0.046.
Prostatype Genomics AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.32.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Prostatype Genomics AB  (OSTO:PROGEN) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Prostatype Genomics AB Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Prostatype Genomics AB (OSTO:PROGEN) Business Description

Traded in Other Exchanges
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines